Clinical Trials
1
Active:0
Completed:1
Trial Phases
1 Phases
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Not Applicable
1 (100.0%)Assessment of Performance and Safety of an Asymmetric Balloon in the Treatment of Intranasal Bleeding Managed in an Emergency Setting
Not Applicable
Completed
- Conditions
- Epistaxis
- First Posted Date
- 2019-04-11
- Last Posted Date
- 2019-09-03
- Lead Sponsor
- Dianosic
- Target Recruit Count
- 10
- Registration Number
- NCT03912051
- Locations
- 🇫🇷
CHU Strasbourg, Strasbourg, Grand Est, France
News
Aptar Pharma Partners with Dianosic to Develop Novel Bioresorbable Intranasal Drug Delivery Platform
Aptar Pharma and French biotech Dianosic have formed an exclusive partnership to develop the Active Resorbable Intranasal Scaffold (ARIS) technology platform for treating chronic allergic rhinitis and chronic rhinosinusitis.